Longevity.Technology notes that Alkeus Pharmaceuticals, Inc. reports that its oral therapy slowed vision loss in a Stargardt disease trial adding encouraging clinical data for a condition with limited treatment options.
Public source
Publisher name
Public post
📌 Daily highlights from the world of longevity and healthspan: Celularity Inc. has secured a major manufacturing deal with Muse Cell Innovations®, supporting the US pro…
Company
Longevity.Technology
The #1 destination for daily news and insights on the fast-growth longevity market. LCW:the gateway to longevity clinics
- Industry
- Information Services
- Location
- London, GB
- Company size
- 11–50 employees
About Longevity.Technology
Just how close is technology that will enable humans to have hyper-extended lifespans? Closer than you think. Our mission is to bring together innovators, researchers, insurers, policy-makers, practitioners and commentators to address the new and fast-growing science and investment category that will shape the future of both the world’s population and the global economy: LONGEVITY
See moreLatest activity
Latest activity from Longevity.Technology
17 signals
People
Longevity.Technology announced that ex-Genentech exec Dr. Prasun Mishra is named to steer science toward the clinic for Longevica Therapeutics, Inc.
Legal & Regulatory
Longevity.Technology notes that Daewoong Pharmaceutical has received a newly allowed US patent covering its experimental lipid delivery system for an mRNA platform for reprogramming aged cells.
Partnerships
Longevity.Technology secured a licensing deal for Amprion's misfolded-protein test to bring it closer to European trial sites for neurodegenerative drug development.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Longevica Therapeutics, Inc.
Longevica Therapeutics, Inc. leverages its $13M, 16,000-subject in vivo longevity dataset and proprietary AI platform to accelerate healthspan-extending therapeutics into the clinic.
Research & Knowledge
LinkGevity
LinkGevity published a new paper co-authored by Dr. Carina Kern, Serena Kern-Libera, Nikodem Grzesiak, Dr Annalisa Jenkins OBE, Guy Coughlan, Prof Damian Bailey, and Prof Richard Faragher titled The Longevity Dividend: Why governments and markets must catch up exploring the implications of a potential paradigm shift presented by new system-level therapeutics.
Research & Knowledge
CB Insights
CB Insights built the HLTH Insights Hub to help people understand market shifts in healthy aging and longevity before the conference.
Legal & Regulatory
The Alliance for Longevity Initiatives
The Alliance for Longevity Initiatives notes that the first draft of the bipartisan Cures in Care Initiative bill is expected this fall.
Research & Knowledge
Biolongevity